Stocks and Investing
Stocks and Investing
Tue, May 9, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Maintained (VIRX) at Buy with Decreased Target to $7 on, May 9th, 2023
Gregory Renza of RBC Capital, Maintained "Viracta Therapeutics, Inc." (VIRX) at Buy with Decreased Target from $8 to $7 on, May 9th, 2023.
Gregory has made no other calls on VIRX in the last 4 months.
There are 3 other peers that have a rating on VIRX. Out of the 3 peers that are also analyzing VIRX, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Gregory
- Andrew Berens of "SVB Securities" Maintained at Buy and Held Target at $11 on, Monday, May 8th, 2023
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $16 on, Monday, March 27th, 2023
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Tuesday, March 14th, 2023
Contributing Sources